Spots Global Cancer Trial Database for cd19
Every month we try and update this database with for cd19 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04648475 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT05673447 | Diffuse Large B... | anti-CD19 CAR N... | 18 Years - 70 Years | Changhai Hospital | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | NCT04134936 | Diffuse Large B... | Tafasitamab Tafasitamab plu... | 18 Years - | MorphoSys AG | |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | NCT04156178 | B Cell Lymphoma B Cell Leukemia | CD20-CD19 cCAR ... | - | iCell Gene Therapeutics | |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | NCT03774654 | Refractory B-Ce... Refractory B-Ce... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... | CD19.CAR-aNKT c... | 3 Years - 75 Years | Baylor College of Medicine | |
| A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT04594642 | B-cell Non Hodg... Diffuse Large B... High-grade B-ce... Follicular Lymp... | AZD0486 IV | 18 Years - 130 Years | AstraZeneca | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL | NCT04206943 | Acute Lymphobla... Non Hodgkin Lym... | Car-T Cell Ther... | 3 Years - 65 Years | Acibadem University | |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | NCT04162353 | Multiple Myelom... Refractory Mult... Plasmacytoid; L... | BCMA-CD19 cCAR ... | - | iCell Gene Therapeutics | |
| CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma | NCT04661020 | Non-hodgkin Lym... | CD19 CAR-T cell... | 18 Years - | Zhejiang University | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04649983 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 2 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | NCT05702853 | B-cell Non Hodg... Chronic Lymphoc... | Cyclophosphamid... Fludarabine Inj... CD19-CD34t meta... | 18 Years - | Medical University of South Carolina | |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies | NCT03125577 | B-cell Malignan... | 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... | 6 Months - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | NCT06180174 | B Cell Lymphoma Non Hodgkin Lym... | MC-1-50 | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | NCT03573700 | Acute Lymphobla... Acute Lymphobla... | Cyclophosphamid... Fludarabine Mesna CliniMACS CD19- specific ... | - 21 Years | St. Jude Children's Research Hospital | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04649983 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 2 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | NCT06056752 | B-cell Acute Ly... | QH103 Cell Inje... Fludarabine Cyclophosphamid... | 14 Years - | Anhui Provincial Hospital | |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | NCT06116110 | Non Hodgkin Lym... | Long-term Follo... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma | NCT04296461 | B-cell Non-Hodg... | Welgenaleucel | 20 Years - 70 Years | UWELL Biopharma | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies | NCT01957579 | Blood Cancer Advanced B Cell... | MEDI-551 | 20 Years - 130 Years | AstraZeneca | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | NCT04134936 | Diffuse Large B... | Tafasitamab Tafasitamab plu... | 18 Years - | MorphoSys AG | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) | NCT01685008 | Non-Hodgkin Lym... | MOR00208 (forme... | 18 Years - | MorphoSys AG | |
| Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma | NCT06047197 | Recurrent Diffu... Refractory Diff... | RC19D2 cell inj... | 18 Years - | Beijing Yongtai Ruike Biotechnology Company Ltd | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | NCT03271515 | Leukemia Lymphoma | anti-CD19 anti-... | 18 Years - 70 Years | Beijing Doing Biomedical Co., Ltd. | |
| CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | NCT05168748 | Acute Lymphobla... | IMJ995 single a... | 1 Year - | Novartis | |
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04648475 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | NCT04532281 | Acute Lymphobla... Non-Hodgkin Lym... | Murine CD19 CAR... | - | Zhejiang University | |
| A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | NCT05334823 | Acute Lymphobla... Relapsed Pediat... Refractory Acut... | pCAR-19B cells | 3 Years - 21 Years | Chongqing Precision Biotech Co., Ltd | |
| Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | NCT01087294 | Leukemia, B-cel... Lymphoma, Hodgk... Lymphoma, Non-h... Lymphoma, B-Cel... | Allogeneic stem... Anti-CD19-chime... Leukapheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | NCT05015972 | B-cell Lymphoma | CTA30X UCAR-T i... | 3 Years - 70 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | NCT03016377 | Acute Lymphobla... Immune System D... Immunoprolifera... | iC9-CAR19 cells Rimiducid Cyclophosphamid... Fludarabine | 3 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | NCT01853631 | Non-Hodgkin Lym... Chronic Lymphoc... Acute Lymphocyt... | Dose Escalation... Expansion Phase... | - 75 Years | Baylor College of Medicine | |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | NCT04236011 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | NCT04782193 | B Cell Lymphoma | CD19 and CD22 t... | 2 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | NCT05571540 | B-cell Acute Ly... B-ALL | U-CAR-T Cells (... | 2 Years - 75 Years | Kunming Hope of Health Hospital | |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | NCT05932173 | B-Cell Leukemia B-Cell Lymphoma B-cell Tumors | Anti-CD19 Autol... | 2 Years - 75 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | NCT05015972 | B-cell Lymphoma | CTA30X UCAR-T i... | 3 Years - 70 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | NCT04156243 | B Cell Lymphoma B Cell Leukemia | CD19 CARvac T c... | - | iCell Gene Therapeutics | |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) | NCT01685021 | Acute Lymphobla... | MOR00208 (forme... | 16 Years - | MorphoSys AG | |
| A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia | NCT01683279 | B Cell Leukemia | Autologous CD19... | 1 Year - 26 Years | Seattle Children's Hospital | |
| A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies | NCT03050190 | B-cell Malignan... | Therapeutic 4SC... | 6 Months - | Shenzhen Geno-Immune Medical Institute | |
| A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT04231747 | Lymphoma Non-Ho... Agressive Lymph... Diffuse-large B... | CC-97540 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT04594642 | B-cell Non Hodg... Diffuse Large B... High-grade B-ce... Follicular Lymp... | AZD0486 IV | 18 Years - 130 Years | AstraZeneca | |
| Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | NCT04271800 | Leukemia Lymphoma Leukemia, B-Cel... Leukemia, Lymph... | CD19 CAR-T cell... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | NCT05365659 | B-cell Non-Hodg... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... B-cell Lymphoma | IKS03 | 18 Years - | Iksuda Therapeutics Ltd. | |
| A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia | NCT03330691 | Leukemia Lymphoma | Patient-derived... | - 30 Years | Seattle Children's Hospital | |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | NCT04617704 | Multiple Myelom... | GC012F injectio... | 18 Years - | Shanghai Changzheng Hospital | |
| Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | NCT05333302 | B-cell Acute Ly... Lymphoblastic B... | CD19 CAR-T-cell... Tocilizumab | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | NCT04214886 | B-Cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... | Fludarabine Cyclophosphamid... CD19-CD34 CAR t... | 18 Years - | Loyola University | |
| CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | NCT04214886 | B-Cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... | Fludarabine Cyclophosphamid... CD19-CD34 CAR t... | 18 Years - | Loyola University | |
| CD19-targeting CAR T Cells for B Cell Lymphoma | NCT02547948 | B Cell Lymphoma | CD19-targeting ... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | NCT05571540 | B-cell Acute Ly... B-ALL | U-CAR-T Cells (... | 2 Years - 75 Years | Kunming Hope of Health Hospital | |
| A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia | NCT01683279 | B Cell Leukemia | Autologous CD19... | 1 Year - 26 Years | Seattle Children's Hospital | |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT05626322 | Diffuse Large B... | Maplirpacept Tafasitamab Lenalidomide | 18 Years - | Pfizer | |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT05626322 | Diffuse Large B... | Maplirpacept Tafasitamab Lenalidomide | 18 Years - | Pfizer | |
| A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | NCT04532281 | Acute Lymphobla... Non-Hodgkin Lym... | Murine CD19 CAR... | - | Zhejiang University | |
| CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | NCT04156243 | B Cell Lymphoma B Cell Leukemia | CD19 CARvac T c... | - | iCell Gene Therapeutics | |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL | NCT04206943 | Acute Lymphobla... Non Hodgkin Lym... | Car-T Cell Ther... | 3 Years - 65 Years | Acibadem University | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | NCT05639179 | B-cell Acute Ly... B-ALL | UCAR-T Cells | 2 Years - 75 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
